Sunday 18 October 2026
Export BNTC’s income statement to Excel — free account
Benitec Biopharma Limited
BNTC Healthcare Biotechnology
In the quarter to June 2026, EPS fell 11.3%, free cash flow grew 38.9% and total debt fell 46.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
8.11
0.35
−4.14%
Follow BNTC
Benitec Biopharma Limited (BNTC) P/E ratio
Benitec Biopharma Limited has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 51.3× (April 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| 12 more quarters | Free account |
Against its own ten years
Low 0.0×
High 51.3×
Ten-year median
0.0×
Current reading's percentile
84
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SRZN Surrozen, Inc. compare | n/m |
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| FULC Fulcrum Therapeutics, Inc. compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| BNTC Benitec Biopharma Limited | n/m |
| OCGN Ocugen, Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| ARCT Arcturus Therapeutics Holdings Inc. compare | n/m |
| AGEN Agenus Inc. compare | 2.3× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)